loader image
Saturday, February 22, 2025
43.7 F
McAllen
We Welcome your Press Release
- Advertisement -

McAllen Officially Cleared from Hurricane Harvey Path by National Weather Service

Translate to Spanish or other 102 languages!

 Mega Doctor News

- Advertisement -

(McAllen, TX) Earlier today, the National Weather Service cleared McAllen from receiving any direct impact from Hurricane Harvey.

City of McAllen administration and emergency management officials have been closely monitoring the forecast and were ready to take any appropriate action in response to the weather situation.

“The safety and security of our community is of utmost importance to us,” said McAllen City Manager Roel “Roy” Rodriguez.  “We were ready to deploy, when and if any response was necessary.”

- Advertisement -

The City of McAllen urges residents to keep vigilant to media and weather advisories and that any travel north should be carefully evaluated.  The NWS is forecasting a substantial amount of rain in the Houston, San Antonio, Corpus Christi triangle that could be measured in feet.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

UPDATE: Measles Outbreak

Mega Doctor News Mega Doctor News  As of February 18, 2025, the Texas...

DHR Health Celebrates 100th Ion Robotic-Assisted Bronchoscopy

DHR Health, a leader in healthcare serving the Rio Grande Valley, announced today that Dr. Federico Vallejo, pulmonologist, has successfully performed his 100th Ion robotic-assisted bronchoscopy.

DHR Health: Pioneering Alzheimer’s Treatment Breakthrough South of San Antonio

DHR Health, a leader in healthcare innovation, proudly announced today its groundbreaking achievement as the first hospital south of San Antonio to successfully administer Leqembi, an FDA-approved medication for the early treatment of Alzheimer’s disease. This milestone demonstrates their expertise and is a significant advancement in healthcare for the Rio Grande Valley.

FDA Approves First CRISPR Gene Therapy to Treat Sickle Cell Disease

Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older.
- Advertisement -
×